Bibliografía del artículo
1. Gänsslein M. Über Inhalation von Insulin. Klin Wochenschr 1925; 4:71.
2. Heubner W, De Jongh SE, Laquer E. Über Inhalation von Insulin. Klin Wochenschr 1924; 3:2342-3.
3. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005; 143:549-58.
4. DeFronzo RA, Bergenstal RM, Cefalu WT et al. Efficiacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-wk, randomized, comparative trial. Diabetes Care 2005; 28(8):1922-8.
5. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27(10):2356-62.
6. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28(7):1630-5.
7. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27(11): 2622-7.
8. Rosenstock J, Cappeleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27(6):1318-23.
9. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28(2): 427-428.
10. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90(6):3287-94.
11. Heise T, Bott S, Tusek C et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005; 28(9):2161-9.
12. Dumas R, Krasner AS, England RD, Riese RJ, Teeter JG. Immunologic response to Exubera in patients with type 1 diabetes is not associated with functional evidence of airway sensitization. [abstract] Diabetes 2005; 54 Suppl. 1:A108.
13. Skyler J. for the Exubera Phase II Study Group. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes 2004; 53 Suppl. 2:A 115; 486-P.
14. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes management system. Br J Clin Pharmacol 2005; 59(5):546-51.
15. Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004; 6(4):466-72.
16. Boyd B, Noymer P, Liu K et al. Effect of gender and device mouthpiece shape on bolus insulin aerosol delivery using the AERx pulmonary delivery system. Pharm Res 2004; 21(10):1776-82.
17. Boss AH, Rave K,Cheatham W, Heise T. Inhaled Techosphere® Insulin: Glucose elimination at the right time? [abstract] Diabetes 2005; 54 Suppl. 1:A109.
18. Rosenstock J, Baughman RA, Rivera-Schaub T et al. A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled Technosphere® Insulin in patients with type 2 diabetes (T2DM). [abstract] Diabetes 2005; 54 Suppl. 1:A88.
19. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165:1337-44.
20. Kjellstrom T, Malmquist J. Insulin effects on collagen and protein production in cultured human skin fibroblasts from diabetic and non-diabetic subjects. Horm Metab Res 1984; 16:168-73.